Hanall Biopharma Co.,Ltd
KRX:009420.KS
44950 (KRW) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) KRW.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 134,909.838 | 109,995.419 | 101,594.444 | 88,602.27 | 108,452.042 | 91,839.351 | 84,230.756 | 82,881.524 | 80,022.56 | 80,879.668 | 74,228.314 | 76,027.305 | 87,701.601 | 106,903.737 | 98,682.408 | 91,890.326 | 82,485.563 |
| Cost of Revenue
| 61,242.558 | 48,024.129 | 41,261.831 | 37,951.232 | 45,671.625 | 42,813.724 | 41,552.077 | 44,379.161 | 43,122.296 | 40,835.084 | 42,477.936 | 40,574.477 | 43,315.648 | 50,746.227 | 48,394.951 | 40,257.308 | 35,106.225 |
| Gross Profit
| 73,667.279 | 61,971.29 | 60,332.613 | 50,651.038 | 62,780.417 | 49,025.627 | 42,678.679 | 38,502.363 | 36,900.264 | 40,044.584 | 31,750.378 | 35,452.828 | 44,385.953 | 56,157.51 | 50,287.457 | 51,633.018 | 47,379.338 |
| Gross Profit Ratio
| 0.546 | 0.563 | 0.594 | 0.572 | 0.579 | 0.534 | 0.507 | 0.465 | 0.461 | 0.495 | 0.428 | 0.466 | 0.506 | 0.525 | 0.51 | 0.562 | 0.574 |
| Reseach & Development Expenses
| 23,083.133 | 16,498.472 | 10,462.423 | 9,316.282 | 10,050.61 | 10,544.733 | 9,789.696 | 9,002.815 | 6,065.993 | 7,794.753 | 9,507.388 | 7,923.775 | 7,531.566 | 6,536.343 | 6,070.144 | 6,278.891 | 4,673.923 |
| General & Administrative Expenses
| 2,502.788 | 2,304.565 | 2,218.261 | 2,144.982 | 2,958.315 | 3,724.877 | 4,344.093 | 5,333.001 | 6,927.333 | 6,333.696 | 6,443.306 | 6,025.235 | 11,378.133 | 7,640.432 | 8,697.637 | 9,436.744 | 11,933.511 |
| Selling & Marketing Expenses
| 23,185.571 | 20,931.349 | 18,305.162 | 15,234.263 | 13,859.794 | 10,094.097 | 6,336.029 | 4,730.973 | 6,192.795 | 5,148.294 | 8,957.536 | 4,585.503 | 8,899.346 | 15,936.372 | 12,185.589 | 13,645.983 | 8,624.505 |
| SG&A
| 48,171.258 | 23,235.914 | 20,523.423 | 17,379.245 | 16,818.109 | 13,818.974 | 10,680.122 | 10,063.974 | 13,120.128 | 11,481.99 | 15,400.842 | 10,610.738 | 20,277.479 | 23,576.804 | 20,883.226 | 23,082.727 | 20,558.016 |
| Other Expenses
| -669.454 | 20,731.117 | 19,247.648 | 18,020.323 | 18,822.093 | 246.417 | 338.703 | 520.861 | -602.059 | 388.318 | 909.283 | 621.932 | 37.271 | -1,345.507 | -255.239 | -636.571 | 173.948 |
| Operating Expenses
| 71,923.845 | 60,465.503 | 50,233.494 | 44,715.85 | 45,690.812 | 43,551.799 | 39,138.666 | 38,216.962 | 41,180.212 | 39,229.321 | 44,733.191 | 38,515.936 | 51,126.26 | 49,311.001 | 46,269.535 | 50,483.742 | 49,004.702 |
| Operating Income
| 1,743.435 | 2,310.968 | 10,099.119 | 8,484.615 | 17,089.605 | 5,473.828 | 3,540.013 | 285.401 | -4,279.948 | 815.264 | -12,982.813 | -3,063.108 | -10,018.172 | 6,846.509 | 4,017.92 | 1,149.278 | -1,625.362 |
| Operating Income Ratio
| 0.013 | 0.021 | 0.099 | 0.096 | 0.158 | 0.06 | 0.042 | 0.003 | -0.053 | 0.01 | -0.175 | -0.04 | -0.114 | 0.064 | 0.041 | 0.013 | -0.02 |
| Total Other Income Expenses Net
| 1,527.998 | -381.538 | -1,397.029 | 10,740.674 | 365.616 | -1,477.42 | -913.396 | 1,388.206 | -545.054 | -13,572.378 | -7,597.473 | -909.225 | -6,927.554 | -5,099.257 | -2,604.667 | 550.684 | -271.677 |
| Income Before Tax
| 3,271.432 | 1,929.43 | 8,702.09 | 19,225.289 | 17,455.221 | 3,996.408 | 2,626.617 | 1,673.607 | -4,825.001 | -12,757.114 | -20,580.286 | -3,972.333 | -13,667.861 | 1,747.252 | 1,413.255 | 1,699.96 | -1,897.041 |
| Income Before Tax Ratio
| 0.024 | 0.018 | 0.086 | 0.217 | 0.161 | 0.044 | 0.031 | 0.02 | -0.06 | -0.158 | -0.277 | -0.052 | -0.156 | 0.016 | 0.014 | 0.018 | -0.023 |
| Income Tax Expense
| -306.075 | 1,677.956 | -194.047 | -539.21 | -1,719.129 | 696.305 | -3,186.637 | -352.419 | 2,252.356 | -99.029 | 918.61 | -1,049.737 | 857.879 | 1,533.594 | 831.303 | 529.935 | -867.333 |
| Net Income
| 3,508.608 | 251.474 | 8,896.137 | 19,764.499 | 19,174.35 | 3,300.102 | 5,813.254 | 2,026.026 | -7,077.357 | -12,658.085 | -21,498.897 | -2,922.595 | -14,525.74 | 213.659 | 581.952 | 1,170.025 | -1,029.708 |
| Net Income Ratio
| 0.026 | 0.002 | 0.088 | 0.223 | 0.177 | 0.036 | 0.069 | 0.024 | -0.088 | -0.157 | -0.29 | -0.038 | -0.166 | 0.002 | 0.006 | 0.013 | -0.012 |
| EPS
| 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 | 114 | 40 | -159 | -314 | -529 | -78.97 | -409.48 | 6 | 17 | 34 | -30 |
| EPS Diluted
| 69.21 | 4.95 | 173.74 | 386.19 | 374.67 | 64.48 | 114 | 40 | -159 | -314 | -529 | -78.97 | -409.48 | 6 | 17 | 34 | -30 |
| EBITDA
| 4,990.38 | 5,363.621 | 12,976.757 | 11,378.834 | 22,546.996 | 11,933.77 | 7,857.823 | 2,626.316 | -2,103.703 | 3,738.53 | -11,370.118 | 233.87 | -4,678.336 | 8,141.264 | 7,426.413 | 4,521.646 | 1,838.514 |
| EBITDA Ratio
| 0.037 | 0.049 | 0.128 | 0.128 | 0.208 | 0.13 | 0.093 | 0.032 | -0.026 | 0.046 | -0.153 | 0.003 | -0.053 | 0.076 | 0.075 | 0.049 | 0.022 |